94 related articles for article (PubMed ID: 24654994)
1. A nationwide cross-sectional overview of patients with rheumatoid arthritis followed in outpatient specialty clinics in Finland.
Aaltonen KJ; Sokka T; Möttönen T; Korpela M; Komulainen R; Uusitalo T; Salomaa S; Uutela T; Valleala H; Rami Study Group
Scand J Rheumatol; 2014; 43(4):286-90. PubMed ID: 24654994
[TBL] [Abstract][Full Text] [Related]
2. Rituximab therapy in patients with rheumatoid arthritis refractory or with contraindication to anti-tumour necrosis factor drugs: real-life experience in Finnish patients.
Valleala H; Korpela M; Möttönen T; Hienonen-Kempas T; Kauppi M; Hannonen P; Leirisalo-Repo M
Scand J Rheumatol; 2009; 38(5):323-7. PubMed ID: 19585384
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of patients with rheumatoid arthritis in Qatar: a cross-sectional study.
Lutf A; Poil AR; Hammoudeh M
Int J Rheum Dis; 2014 Jan; 17(1):63-5. PubMed ID: 24472269
[TBL] [Abstract][Full Text] [Related]
4. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial.
Karlsson JA; Neovius M; Nilsson JÅ; Petersson IF; Bratt J; van Vollenhoven RF; Ernestam S; Geborek P
Ann Rheum Dis; 2013 Dec; 72(12):1927-33. PubMed ID: 23196701
[TBL] [Abstract][Full Text] [Related]
5. Three out of four disease-modifying anti-rheumatic drug-naïve rheumatoid arthritis patients meet 28-joint Disease Activity Score remission at 12 months: results from the FIN-ERA cohort.
Rannio T; Asikainen J; Hannonen P; Yli-Kerttula T; Ekman P; Pirilä L; Kuusalo L; Mali M; Puurtinen-Vilkki M; Kortelainen S; Paltta J; Taimen K; Kauppi M; Laiho K; Nyrhinen S; Mäkinen H; Isomäki P; Uotila T; Aaltonen K; Kautiainen H; Sokka T
Scand J Rheumatol; 2017 Nov; 46(6):425-431. PubMed ID: 28367663
[TBL] [Abstract][Full Text] [Related]
6. Short-term efficacy of etanercept plus methotrexate vs combinations of disease-modifying anti-rheumatic drugs with methotrexate in established rheumatoid arthritis.
Fleischmann R; Koenig AS; Szumski A; Nab HW; Marshall L; Bananis E
Rheumatology (Oxford); 2014 Nov; 53(11):1984-93. PubMed ID: 24907147
[TBL] [Abstract][Full Text] [Related]
7. Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies.
Saunders SA; Capell HA; Stirling A; Vallance R; Kincaid W; McMahon AD; Porter DR
Arthritis Rheum; 2008 May; 58(5):1310-7. PubMed ID: 18438851
[TBL] [Abstract][Full Text] [Related]
8. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
9. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial.
O'Dell JR; Leff R; Paulsen G; Haire C; Mallek J; Eckhoff PJ; Fernandez A; Blakely K; Wees S; Stoner J; Hadley S; Felt J; Palmer W; Waytz P; Churchill M; Klassen L; Moore G
Arthritis Rheum; 2002 May; 46(5):1164-70. PubMed ID: 12115219
[TBL] [Abstract][Full Text] [Related]
10. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study.
van Halm VP; Nurmohamed MT; Twisk JW; Dijkmans BA; Voskuyl AE
Arthritis Res Ther; 2006; 8(5):R151. PubMed ID: 16984661
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of efficacy and tolerability of triple combination therapy (methotrexate + sulfasalazine + hydroxychloroquine) with methotrexate monotherapy in patients with rheumatoid arthritis].
Gubar' EE; Bochkova AG; Bunchuk NV
Ter Arkh; 2008; 80(5):25-30. PubMed ID: 18590110
[TBL] [Abstract][Full Text] [Related]
12. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
Proudman SM; Keen HI; Stamp LK; Lee AT; Goldblatt F; Ayres OC; Rischmueller M; James MJ; Hill CL; Caughey GE; Cleland LG
Semin Arthritis Rheum; 2007 Oct; 37(2):99-111. PubMed ID: 17391739
[TBL] [Abstract][Full Text] [Related]
13. Remission of rheumatoid arthritis and potential determinants: a national multi-center cross-sectional survey.
Wang GY; Zhang SL; Wang XR; Feng M; Li C; An Y; Li XF; Wang LZ; Wang CH; Wang YF; Yang R; Yan HM; Wang GC; Lu X; Liu X; Zhu P; Chen LN; Jin HT; Liu JT; Guo HF; Chen HY; Xie JL; Wei P; Wang JX; Liu XY; Sun L; Cui LF; Shu R; Liu BL; Yu P; Zhang ZL; Li GT; Li ZB; Yang J; Li JF; Jia B; Zhang FX; Tao JM; Lin JY; Wei MQ; Liu XM; Ke D; Hu SX; Ye C; Han SL; Yang XY; Li H; Huang CB; Gao M; Lai B; Cheng YJ; Li XF; Song LJ; Yu XX; Wang AX; Wu LJ; Wang YH; He L; Sun WW; Gong L; Wang XY; Wang Y; Zhao Y; Li XX; Wang Y; Zhang Y; Su Y; Zhang CF; Mu R; Li ZG
Clin Rheumatol; 2015 Feb; 34(2):221-30. PubMed ID: 25413735
[TBL] [Abstract][Full Text] [Related]
14. Patients with rheumatoid arthritis have better functional and working ability but poorer general health and higher comorbidity rates today than in the late 1990s.
Uutela T; Kautiainen H; Järvenpää S; Salomaa S; Hakala M; Häkkinen A
Scand J Rheumatol; 2015 May; 44(3):173-81. PubMed ID: 25438985
[TBL] [Abstract][Full Text] [Related]
15. Retention rates of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis.
Agarwal S; Zaman T; Handa R
Singapore Med J; 2009 Jul; 50(7):686-92. PubMed ID: 19644623
[TBL] [Abstract][Full Text] [Related]
16. Effects of disease modifying anti-rheumatic drugs on subclinical atherosclerosis and endothelial dysfunction which has been detected in early rheumatoid arthritis: 1-year follow-up study.
Guin A; Chatterjee Adhikari M; Chakraborty S; Sinhamahapatra P; Ghosh A
Semin Arthritis Rheum; 2013 Aug; 43(1):48-54. PubMed ID: 23415602
[TBL] [Abstract][Full Text] [Related]
17. The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis.
Chen HA; Lin KC; Chen CH; Liao HT; Wang HP; Chang HN; Tsai CY; Chou CT
Ann Rheum Dis; 2006 Jan; 65(1):35-9. PubMed ID: 15975966
[TBL] [Abstract][Full Text] [Related]
18. Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study.
Gibofsky A; Palmer WR; Goldman JA; Lautzenheiser RL; Markenson JA; Weaver A; Schiff MH; Keystone EC; Paulus HE; Harrison MJ; Whitmore JB; Leff JA
Curr Med Res Opin; 2006 Jan; 22(1):169-83. PubMed ID: 16393443
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of triple DMARD therapy in patients with RA with suboptimal response to methotrexate.
O'Dell JR; Haire C; Erikson N; Drymalski W; Palmer W; Maloley P; Klassen LW; Wees S; Moore GF
J Rheumatol Suppl; 1996 Mar; 44():72-4. PubMed ID: 8833058
[TBL] [Abstract][Full Text] [Related]
20. Outcome of patients with rheumatoid arthritis: cross-sectional study of a single-center real-world inception cohort.
Ling E; Ofer-Shiber S; Goren O; Molad Y
Isr Med Assoc J; 2013 Dec; 15(12):758-62. PubMed ID: 24449980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
